ArticleActa psychiatrica Scandinavica2025
Psychopathic Traits Associate With Later Schizophrenia.
Article in Acta psychiatrica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An exploratory study on the impact of medication usage patterns on relapse among community schizophrenia patients.BMC psychiatry · 2026Article
- Psychopathic Traits Associate With Later Schizophrenia.Acta psychiatrica Scandinavica · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionDespite well-known diagnostic and neurobiological overlaps between psychopathic traits and schizophrenia, it has remained unclear whether psychopathic traits increase the risk for later schizophrenia. Former studies have proven only a weak correlation between psychopathy and DSM axis I diagnoses.
methodsWe combined data from individuals who underwent forensic psychiatric evaluations (FPEs) at Niuvanniemi Hospital between 1984 and 1993 with the records from the Care Register for Health Care to examine the relationship between psychopathic traits, measured by the Psychopathy Checklist-Revised (PCL-R), and the development of schizophrenia following the evaluation. We conducted survival analyses using Kaplan-Meier estimates and Cox proportional hazards models, with a follow-up period of up to 40 years. Mortality data were obtained from the National Death Registry. Statistical analyses were adjusted for age, sex, criminal responsibility, and substance abuse disorder at the time of the FPE.
resultsThe study included 341 individuals (278 males [81.51%] and 63 females [18.49%], mean [SD] age 33.52 [11.49]) who were adults, criminally responsible, and did not have a psychotic illness, severe mental disability, or brain damage at FPE. Compared to individuals with total PCL-R scores less than or equal to 10, those with scores of 11-24 (adjusted hazard ratio [aHR] = 5.30, 95% CI = 1.21-23.25) and 25 or higher (aHR = 9.33, 95% CI = 2.04-42.76) had a significantly higher risk of later hospitalization due to schizophrenia. Also, individuals classified as psychopathic (PCL-R ≥ 25) had a significantly higher risk of developing schizophrenia compared with those classified as non-psychopathic (PCL-R < 25): aHR = 2.37, 95% CI =1.17-4.80. A total of 20% of psychopaths developed schizophrenia over the follow-up.
conclusionsThe novel results suggest that there is a link between higher PCL-R scores and a higher risk of later-life schizophrenia outbreak among non-psychotic individuals undergoing FPE. Multiple factors can explain the finding, including substance use and mutual risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.